Caterina Cariti
Turin, 10126, Italy
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 22 publications
Drug Survival, Safety, and Effectiveness of Secukinumab for up to 5 Years in Patients with Psoriasis and Psoriatic Arthritis: A Long-Term Real-Life Experience.
Journal: Journal of personalized medicine
Published: June 07, 2024
Clinical characteristics and response to biological therapies for inverse psoriasis: a real-life comparison between the therapeutic effects of anti-IL-23 and anti-IL-17 agents.
Journal: International journal of dermatology
Published: January 14, 2024
Drug survival and clinical effectiveness of secukinumab, ixekizumab, brodalumab, guselkumab, risankizumab, tildrakizumab for psoriasis treatment.
Journal: Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG
Published: July 12, 2023
Comparison between brodalumab, secukinumab and ixekizumab effectiveness and drug survival: A real-life experience on 638 patients with psoriasis.
Journal: Experimental dermatology
Published: March 22, 2023
"Superresponders" at biologic treatment for psoriasis: A comparative study among IL17 and IL23 inhibitors.
Journal: Experimental dermatology
Published: November 28, 2022
Efficacy of anti-IL-23 and anti-IL-17 after adalimumab failure in psoriatic patients.
Journal: Journal of the European Academy of Dermatology and Venereology : JEADV
Published: November 21, 2022
Drug survival and efficacy of anti-interleukin 23 biologics in psoriasis: a comparative study on different agents.
Journal: Clinical and experimental dermatology
Published: November 18, 2022
Brodalumab efficacy in bio-naïve psoriasis patients: real-life experience of 202 subjects up to 48 weeks.
Journal: The Journal of dermatological treatment
Published: September 14, 2022
Tildrakizumab in real-life shows good efficacy in moderate-to-severe psoriasis regardless of previous use of biologic drugs and joint involvement.
Journal: Dermatologic therapy
Published: July 22, 2022
Mask-related acne flares during the COVID era.
Journal: Italian journal of dermatology and venereology
Published: June 16, 2022
Risankizumab shows faster response in bio naïve than in bio-experienced psoriatic patients.
Journal: Journal of the European Academy of Dermatology and Venereology : JEADV
Published: March 15, 2022
Real-life comparison between secukinumab and ixekizumab in the treatment of pustular and erythrodermic psoriasis.
Journal: Journal of the European Academy of Dermatology and Venereology : JEADV
Published: December 09, 2021
Last Updated: 09/26/2026